U.S. Airlines Stock News

NasdaqGS:GLPI
NasdaqGS:GLPISpecialized REITs

What Gaming and Leisure Properties (GLPI)'s Record Results and $2.6 Billion Pipeline Expansion Means For Shareholders

Gaming and Leisure Properties, Inc. recently reported record 2025 results, with revenue rising to US$1.59 billion and net income reaching US$825.11 million, while also declaring a US$0.78 per-share dividend for the first quarter of 2026. Alongside these earnings, the completion of the US$700 million Bally’s Lincoln acquisition and a US$2.6 billion committed development pipeline highlight how GLPI is expanding its casino real estate footprint while keeping leverage below its internal...
NasdaqGS:DOCU
NasdaqGS:DOCUSoftware

Reassessing DocuSign (DOCU) After A 47% Slide And Fresh Valuation Signals

If you are wondering whether DocuSign's current share price reflects its true worth, you are not alone. This article will help you frame that question clearly. With the stock closing at US$44.48 and returns of a 0.8% decline over 7 days, a 22.6% decline over 30 days, a 31.4% decline year to date and a 47.0% decline over 1 year, many investors are reassessing what a fair price looks like for DocuSign. Recent coverage has focused on how DocuSign is repositioning itself within the broader...
NasdaqGS:PAYX
NasdaqGS:PAYXProfessional Services

Paychex Director Buys More Shares As Valuation Flags Potential Upside

Paychex Director Joseph Doody recently acquired additional shares of NasdaqGS:PAYX, signaling increased personal exposure to the company. The insider purchase comes as Paychex shares trade at $91.24 following a 16.0% decline year to date. This transaction adds a fresh data point for investors watching insider activity at Paychex. For investors tracking Paychex, the timing of this insider buying stands out against a weaker recent share performance. The stock is at $91.24, with a 7 day return...
NasdaqGS:CRAI
NasdaqGS:CRAIProfessional Services

Is CRA International (CRAI) Pricing Reflect Longer Term Gains After Recent Pullback

If you are wondering whether CRA International's current share price reflects its real value, you are not alone. The stock has a mix of recent returns that raises fair questions about what it is truly worth. At a last close of US$166.60, CRA International has returned 7.3% over the past week, after a 20.3% decline over 30 days and year to date and 1 year returns of 16.9% and 16.2% declines. The 3 year and 5 year returns sit at 38.1% and 221.5% respectively. These moves come against a...
NYSE:NU
NYSE:NUBanks

Nu Holdings Redraws Growth Story With AI Push And U.S. Charter

Nu Holdings (NYSE:NU) has outlined a global expansion plan that includes significant investment in new international offices. The company has acquired AI firm Hyperplane to deepen its data and machine learning capabilities across its product suite. Nu has secured a conditional U.S. national bank charter, opening the door to offering regulated banking services in the United States. The company has also entered a partnership with the Mercedes AMG PETRONAS F1 Team as part of its global brand...
NYSE:VSTS
NYSE:VSTSCommercial Services

A Look At Vestis (VSTS) Valuation After Q1 Earnings Loss And Reaffirmed 2026 Revenue Outlook

Vestis (VSTS) moved after releasing first quarter 2026 results, which showed lower sales and a net loss. The company also reaffirmed its full year guidance for revenue, projecting results between flat and a 2% decline. See our latest analysis for Vestis. The earnings release and reaffirmed guidance seem to have shifted sentiment in the short term, with a 1-day share price return of 3.91% and a 30-day share price return of 16.50% at a latest share price of $7.98. However, the 1-year total...
NasdaqGS:VRTX
NasdaqGS:VRTXBiotechs

A Look At Vertex Pharmaceuticals (VRTX) Valuation After Strong Results And Growing Casgevy And Journavx Contributions

Vertex Pharmaceuticals (VRTX) drew fresh attention after reporting full year 2025 results, with revenue of US$12.0b and net income of US$3.95b, alongside guidance highlighting contributions from Casgevy and Journavx. See our latest analysis for Vertex Pharmaceuticals. That backdrop has come with a mixed price move, with a 12.48% 90 day share price return and a modest 1.81% 30 day share price return, while the 1 year total shareholder return of 1.52% decline contrasts with a 65.95% gain over...
NYSE:ALB
NYSE:ALBChemicals

Idling Kemerton While Guiding Flat 2026 Output Might Change The Case For Investing In Albemarle (ALB)

Earlier in February 2026, Albemarle said it had idled the last operating train at its Kemerton lithium hydroxide plant in Western Australia, recorded US$245.60 million of long‑lived asset impairments for the December 2025 quarter, and reported a quarterly net loss despite higher sales. At the same time, Albemarle guided to 2026 net sales of US$5.70 billion to US$6.00 billion with flat volumes, while shifting Kemerton into care and maintenance but planning to meet lithium hydroxide demand...
NYSE:TMO
NYSE:TMOLife Sciences

Thermo Fisher Datavant Data Link Draws Focus To TMO Valuation And Risks

Thermo Fisher Scientific (NYSE:TMO) has entered into a data collaboration with Datavant to link real world data with its clinical research operations. The partnership uses Datavant's privacy preserving technology to connect diverse healthcare datasets for clinical studies. The goal is to support study design, patient recruitment, and evidence generation across life sciences research. Thermo Fisher Scientific, trading at $510.93, sits in a challenging period for shareholders, with the stock...
NYSE:VOYA
NYSE:VOYADiversified Financial

A Look At Voya Financial (VOYA) Valuation After New Fixed Income Offering And Shelf Registration

Voya Financial (VOYA) has launched a new fixed income offering of senior, unsecured fixed rate notes, shortly after filing an omnibus shelf registration that covers debt, equity, preferred stock, depositary shares, warrants, and units. See our latest analysis for Voya Financial. Voya’s new notes come after a period where momentum has softened slightly in the short term, with a 30 day share price return of a 1.83% decline. The 1 year total shareholder return of 6.56% and 5 year total...
NYSE:B
NYSE:BMetals and Mining

Barrick Mining IPO Plan Reshapes Gold Exposure And Valuation Outlook

Barrick Mining (NYSE:B) is preparing an IPO of its North American gold assets. The company has not yet confirmed the final structure or timing of the transaction. The move would separate a key regional gold portfolio into a new publicly traded vehicle. The planned IPO comes with Barrick Mining shares at $47.96 and a very large 1 year return and strong multi year gains, including 221.0% over 3 years and 194.9% over 5 years. For existing shareholders, carving out the North American gold...
NYSE:JPM
NYSE:JPMBanks

JPMorgan Trump Account Closures Put Reputational Risk Policies Under Review

JPMorgan Chase (NYSE:JPM) confirmed it closed bank accounts held by former President Donald Trump and his businesses after the January 6, 2021 US Capitol events. New court filings in an ongoing lawsuit allege the closures were politically motivated, while the bank cites reputational risk considerations. The case brings fresh attention to how one of the largest US banks handles high profile clients when legal, political and reputational issues intersect. For you as an investor, this puts a...
NYSE:BLD
NYSE:BLDConsumer Durables

Is It Too Late To Consider TopBuild (BLD) After A 71% One Year Rally?

If you are wondering whether TopBuild is still good value after a strong run, this article will walk through what the current share price could mean for you as an investor. The stock closed at US$518.92, with returns of 6.3% over the last 30 days, 20.3% year to date and 70.8% over 1 year. The 7 day return of a 5.8% decline may have some investors reassessing the balance between opportunity and risk. Recent coverage has focused on TopBuild as a key player in building products and installation...
NasdaqGS:REGN
NasdaqGS:REGNBiotechs

Is Regeneron (REGN) Still Reasonably Priced After Its Multi Year Share Price Run?

If you are wondering whether Regeneron Pharmaceuticals is still priced fairly after a strong multi year run, or if the market is missing something in plain sight, this article will help you weigh what you are really paying for. The stock most recently closed at US$779.67, with returns of 3.5% over 30 days and 74.2% over 5 years, so recent moves and longer term performance give mixed signals on how the market is pricing its potential and risks. Recent headlines around Regeneron have focused...
NasdaqGS:LBTY.A
NasdaqGS:LBTY.ATelecom

Liberty Global (LBTY.A) Is Up 15.2% After Huge 2025 Loss Despite Higher Sales - What's Changed

Liberty Global Ltd. has reported its full-year 2025 results, with sales rising to US$4,878.5 million from US$4,341.9 million, but swinging from a net income of US$1.59 billion to a very large net loss of US$7.14 billion and a basic loss per share from continuing operations of US$20.86. The combination of higher revenue and a very large reported loss raises questions about cost structure, one-off charges, and how resilient the business model really is. We’ll now consider how this sharp move...
NYSE:SNAP
NYSE:SNAPInteractive Media and Services

Snap Reworks Revenue Model As AR Shift And Lawsuit Shape Outlook

Snap (NYSE:SNAP) is shifting more of its revenue mix toward higher margin subscriptions, aiming for a larger base of recurring income. The company has spun off its Specs augmented reality glasses team into a subsidiary and senior executive Scott Myers, who was central to the project, has left. Snap is facing new regulatory and reputational pressure after the Texas Attorney General filed a lawsuit over alleged addictive features and mature content on its platform. Snap comes into these...
NasdaqGS:ABNB
NasdaqGS:ABNBHospitality

Airbnb (ABNB) Is Up 5.4% After Q4 Beat, Buybacks And New Employee Share Plan - What's Changed

In February 2026, Airbnb reported fourth-quarter 2025 revenue of US$2,778 million and net income of US$341 million, with full-year 2025 revenue of US$12.24 billion and net income of US$2.51 billion, alongside completing share repurchases totaling US$6.47 billion across two programs. The company paired these results with a new US$2.32 billion shelf registration for employee share offerings and highlighted product initiatives like Reserve Now, Pay Later and transparent pricing as key drivers...
NasdaqGS:INSM
NasdaqGS:INSMBiotechs

Assessing Insmed (INSM) Valuation After Brinsupri Outperformance And Upgraded 2026 Revenue Guidance

Insmed (INSM) has been in focus after its fourth quarter and full year 2025 earnings, where strong revenue from ARIKAYCE and new drug BRINSUPRI contrasted with a wider net loss and ambitious 2026 sales guidance. See our latest analysis for Insmed. Insmed’s recent earnings and guidance have come alongside a sharp move in the share price, with a 10.86% 7 day share price return and 5.57% 30 day share price return partly offsetting a 21.10% 90 day share price decline. The 1 year total shareholder...
NYSE:CNMD
NYSE:CNMDMedical Equipment

Is It Time To Reassess CONMED (CNMD) After Its Recent Share Price Rebound

If you are wondering whether CONMED's current share price reflects its true worth, this article walks through the key signals that matter for value focused investors. The stock last closed at US$45.14, with a recent return of 8.0% over 7 days and 8.4% over 30 days, set against an 11.4% return year to date and a 25.4% decline over the past year. These moves sit against a backdrop of ongoing interest in medical devices and surgical technologies. Investors are watching how companies like CONMED...
NYSE:QGEN
NYSE:QGENLife Sciences

Is Qiagen (NYSE:QGEN) Pricing Reflect Its DCF Upside And Molecular Diagnostics Momentum

If you are wondering whether Qiagen's current share price offers fair value or a potential gap to fundamentals, you are in the right place. The stock last closed at US$48.57, with returns of 22.1% over 1 year and 2.1% year to date. Over the past week and 30 days it saw declines of 3.7% and 12.7% respectively, which may have changed how the market views its risk and opportunity. Recent news flow around Qiagen has mainly focused on its role in molecular diagnostics and life sciences tools,...
NasdaqGS:ASND
NasdaqGS:ASNDBiotechs

Assessing Ascendis Pharma (ASND) Valuation After A Year Of Strong Returns And Premium P/S Multiple

What Ascendis Pharma’s Recent Trading Signals Tell You Ascendis Pharma (NasdaqGS:ASND) has drawn attention after recent trading left the share price around $225, with a modest gain over the past week but a small decline over the past month. For context, the stock shows a positive total return over the past 3 months and past year. Longer multiyear returns and current fundamentals such as revenue, net income, and valuation metrics shape how some investors are reassessing the risk and reward...
NYSE:AWK
NYSE:AWKWater Utilities

American Water Merger Vote Sets Course For Larger Regulated Utility Growth

American Water Works Company (NYSE:AWK) and Essential Utilities shareholders have overwhelmingly approved an all stock, tax free merger. The combined company will operate under the American Water name and is expected to become the largest regulated water and wastewater utility in the United States. The merger is targeted to close by the end of Q1 2027, subject to regulatory approvals across the involved jurisdictions. For you as an investor following NYSE:AWK, this vote is a key corporate...
NasdaqCM:CORT
NasdaqCM:CORTPharmaceuticals

Is Corcept Therapeutics (CORT) Now An Opportunity After A Sharp 1 Year Share Price Fall?

If you are wondering whether Corcept Therapeutics at around US$34.82 is starting to look interesting on price, you are not alone. The stock has been drawing attention from investors focused on value. The share price has seen a 12.9% decline over the last 7 days, 20.8% over 30 days, 8.8% year to date and 45.2% over 1 year, even though the 3 year and 5 year returns sit at 63.4% and 38.4% respectively. Recent coverage has largely centered on ongoing developments in its pharmaceutical and...
NasdaqCM:QUBT
NasdaqCM:QUBTTech

Quantum Computing Shifts To Integrated Photonics With Luminar And Defense Focus

Quantum Computing Inc. (NasdaqCM:QUBT) has acquired Luminar Semiconductor, adding integrated photonics capabilities to its quantum computing portfolio. The company is shifting its growth focus toward integrated photonics based architectures for quantum information processing. Quantum Computing Inc. is also expanding its contracts with the United States Department of Defense, increasing its exposure to government and defense related work. For you as an investor, this move puts Quantum...